Edwards Lifesciences CORP Form 4 insider transactions

Edwards Lifesciences' Chief Financial Officer, Scott B. Ullem, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences CVP, Daniel J. Lippis, exercised options and sold 1,020 shares of common stock under a pre-arranged trading plan.

Edwards Lifesciences' SVP, Corporate Controller, Andrew M. Dahl, disposed of 262 common shares for tax withholding purposes at $77.57 per share.

Edwards Lifesciences Corporation granted 3,205 restricted stock units to Daveen Chopra, CVP of TMTT & Surgical, as part of its long-term incentive program.

Wayne Markowitz, CVP, JAPAC at Edwards Lifesciences Corp, reported the acquisition of 6,410 restricted stock units and the disposition of 650 shares for tax purposes.

Daveen Chopra, CVP of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences Corp, sold 2,500 shares of common stock for a weighted average price of $81.946 per share.

Edwards Lifesciences Global President Larry Wood sold 8,950 shares of common stock after exercising options, as part of a pre-arranged trading plan.

Daniel J. Lippis, CVP JAPAC at Edwards Lifesciences Corp, sold 4,114 shares of common stock for approximately $79.46 per share under a pre-arranged trading plan.

Annette Bruls, CVP, EMEACLA at Edwards Lifesciences Corp, disposed of 109 shares of common stock at $78.8 per share to satisfy tax withholding obligations.

Edwards Lifesciences CVP, JAPAC Daniel J. Lippis, reported the disposition of 333 common shares at $76.79 each to cover tax withholding obligations.

Edwards Lifesciences Global President Larry L. Wood executed a pre-planned sale of 8,950 shares of common stock after exercising employee stock options.

Edwards Lifesciences CEO Bernard J. Zovighian sold a total of 17,066 shares of common stock in late May and early June 2025, pursuant to a Rule 10b5-1 trading plan.

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences Corp, sold 2,570 shares of common stock for approximately $77.40 per share under a Rule 10b5-1 trading plan.

Daveen Chopra, CVP at Edwards Lifesciences, reported the sale of 1,500 shares of common stock at a price of $75.075 on May 22, 2025.

CEO Bernard J. Zovighian transferred shares of Edwards Lifesciences common stock to a family trust.

CEO Bernard J. Zovighian reports changes in his beneficial ownership of Edwards Lifesciences Corp stock due to tax withholding and a gift.

Donald E. Bobo Jr., CVP of Strategy/Corporate Development at Edwards Lifesciences, disposed of 816 shares of common stock on May 11, 2025, to cover tax obligations.

Daveen Chopra, CVP at Edwards Lifesciences, reported the disposal of 580 shares of common stock on May 11, 2025, at a price of $73.68 per share.

Daniel J. Lippis, CVP of JAPAC at Edwards Lifesciences, disposed of 271 shares of common stock on May 11, 2025, to cover tax obligations.

Scott B. Ullem, CFO of Edwards Lifesciences, reports changes in beneficial ownership of company stock, including the disposal of 1,200 shares to cover tax obligations.

Larry L. Wood, Global President of TAVR & Surg at Edwards Lifesciences, disposed of 988 shares of common stock to cover tax obligations.

Nicholas J. Valeriani, a director at Edwards Lifesciences Corp, acquired 5,564 shares of common stock through a restricted stock unit grant.

Director Ramona Sequeira acquired 3,528 shares of Edwards Lifesciences Corp stock through a restricted stock unit grant.

Director Steven R. Loranger reports receiving restricted stock units and a restricted stock award from Edwards Lifesciences on May 9, 2025.

Director Paul A. Laviolette reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Director Leslie Stone Heisz reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Director Kieran Gallahue reported the acquisition of common stock through restricted stock units and awards granted under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program.

David T. Feinberg, a director at Edwards Lifesciences, acquired 3,528 shares of common stock through a restricted stock unit grant.

Director Leslie C. Davis reports acquisition of 3,528 restricted stock units in Edwards Lifesciences Corp.

Annette Bruls, CVP of EMEACLA at Edwards Lifesciences, reports the acquisition of stock options and restricted stock units.